Economic burden of invasive <i>Escherichia coli</i> disease among older adult patients treated in hospitals in the United States-Reference-Cited by-同舟云学术

Economic burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States

Published:2023-08 Issue:8 Volume:29 Page:873-883
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Hernandez-Pastor Luis¹,Geurtsen Jeroen²,Baugh Bryan³,El Khoury Antoine C.⁴,Kalu Nnanya⁵,Krishnarajah Girishanthy⁵,Gauthier-Loiselle Marjolaine⁶,Bungay Rebecca⁶,Cloutier Martin⁶,Saade Elie⁷

Affiliation:

1. Janssen Pharmaceutica NV, Beerse, Belgium.

2. Janssen Vaccines & Prevention BV, Leiden, the Netherlands.

3. Janssen Research & Development, LLC.

4. Janssen Global Services, LLC, Raritan, NJ.

5. Janssen Scientific Affairs, LLC, Titusville, NJ.

6. Analysis Group, Inc., Montréal, Québec, Canada.

7. Department of Medicine, Case Western Reserve University, Cleveland, OH.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Reference31 articles.

1. Genomics and pathotypes of the many faces ofEscherichia coli

2. Mueller M, Tainter CR. Escherichia coli. StatPearls Publishing; 2023. Accessed April 21, 2023. https://www.ncbi.nlm.nih.gov/books/NBK564298/

3. Epidemiology, Clinical Features, and Antimicrobial Resistance of InvasiveEscherichia ColiDisease in Patients Admitted in Tertiary Care Hospitals

4. Extraintestinal PathogenicEscherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antimicrobial resistance at the human–animal–environment interface: A focus on antimicrobial-resistant Escherichia coli transmission dynamics, clinical implications, and future directions;International Journal of One Health;2024-07

2. Evaluation of Water Quality from the Zimny Sztok Spring (Southern Poland)—Preliminary Results;Sustainability;2024-06-11

3. In Vitro Simulated Hemoperfusion on Seraph®-100 as a Promising Strategy to Counteract Sepsis;Biomedicines;2024-03-05

4. Impact of Invasive Escherichia Coli Disease on Clinical Outcomes and Medical Resource Utilization Among Asian Patients in the United States;Infectious Diseases and Therapy;2024-01-24

5. Escherichia coli Infection Sepsis: An Analysis of Specifically Expressed Genes and Clinical Indicators;Diagnostics;2023-11-27